

# Automated Blood Coagulation Analyzer CA-600 series

## Reference Guide

USA only

**5.00**

**Version:** 5.00

**Date of Issue:** 2024-04

We reserve the right to make changes in the course of technical development without previous notice.

© Siemens Healthineers, 2003–2024. All rights reserved.



**Siemens Healthcare Diagnostics Products GmbH**

Emil-von-Behring-Str. 76

35041 Marburg/Germany

This document is the Siemens Healthineers Reference Guide for the following system: Automated Blood Coagulation Analyzer CA-600 series. It is the only relevant source for assay application information on this system.

The Reference Guide contains a complete list of all assays evaluated and released by Siemens Healthineers. Information in this document supersedes information in earlier versions of the Reference Guide or Application Sheets.

## Trademarks

Actin, BCS, Berichrom, Ci-Trol, Dade, Data-Fi, INNOVANCE, Innovin, Multifibren, Pathromtin and Thromborel are trademarks of Siemens Healthineers.

All other trademarks are the property of their respective owners.

## Disclaimer

Siemens Healthineers has validated the provided instructions, reagents, instrument, software and customizable features for this system to optimize product performance and meet product specifications. User defined modifications are not supported by Siemens Healthineers as they may affect performance of the system and test results. It is the responsibility of the user to validate any modifications made to these instructions, instruments, reagents or software provided by Siemens Healthineers.

---

### Siemens Healthineers Headquarters

Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



### Siemens Healthcare Diagnostics Products GmbH

Emil-von-Behring-Str. 76  
35041 Marburg/Germany

## Revision History

Document	Date	Changes
Reference Guide 5.00	2024-04	<b>New Application Sheets</b> None <b>Deleted Application Sheets</b> None <b>Revised Application Sheets</b> <i>General changes</i> Application Sheets not listed below may contain sections highlighted in blue which indicate editorial corrections without changes to content. These corrections may lead to a higher version of concerned Application Sheets. Version, Release Date: modified
Previous Reference Guide Versions	–	See respective Reference Guide.

# Table of Contents

Revision bar indicates update to previous version.

Version	Application Sheet	Page
	<b>PT</b> .....	<b>5</b>
12	PT seconds / Thromborel® S .....	7
13	PT INR / Thromborel® S .....	11
14	Derived Fibrinogen / Thromborel® S .....	15
13	PT seconds / Dade® Innovin® .....	19
14	PT INR / Dade® Innovin® .....	23
16	Derived Fibrinogen / Dade® Innovin® .....	27
	<b>APTT</b> .....	<b>31</b>
14	APTT / Dade® Actin® Activated Cephaloplastin Reagent .....	33
14	APTT / Dade® Actin® FS Activated PTT Reagent .....	37
14	APTT / Dade® Actin® FSL Activated PTT Reagent .....	41
15	APTT / Pathromtin® SL .....	45
	<b>Fibrinogen</b> .....	<b>49</b>
15	Fibrinogen / Multifibren® U .....	51
14	Fibrinogen / Dade® Thrombin Reagent .....	55
	<b>Thrombin Time/Batroxobin Time</b> .....	<b>61</b>
13	Thrombin time / Test Thrombin Reagent .....	63
12	Batroxobin time / Batroxobin Reagent .....	67
	<b>Clotting Assays</b> .....	<b>71</b>
13	Coagulation Factor VII / Dade® Innovin® .....	73
13	Coagulation Factor VIII / Dade® Actin® FSL Activated PTT Reagent .....	77
13	Protein C / Protein C Reagent .....	83
	<b>Chromogenic Assays</b> .....	<b>87</b>
08	Antithrombin / INNOVANCE® Antithrombin .....	89
14	Antithrombin III / Berichrom® Antithrombin III (A) .....	93
05	Heparin / INNOVANCE® Heparin .....	97
15	Protein C / Berichrom® Protein C .....	103
	<b>Immunoassays</b> .....	<b>107</b>
11	D-dimer / INNOVANCE® D-Dimer .....	109
	<b>Addendum I: General Information to the Applications</b> .....	<b>115</b>
	On-board Stability .....	115
	Reportable Ranges .....	115
	<b>Addendum II: Symbol Names of Required Materials, REF and SMN for all products</b> .....	<b>116</b>





# Application Sheet

## PT seconds / Thromborel® S

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	12
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Pro- tocol
Thromborel® S	<b>REF</b> OUHP53 10 × → 10 mL				PT THS
Ci-Trol <b>CONTROL 1</b>	<b>REF</b> B4244-10 20 × → 1 mL				n/a
Ci-Trol <b>CONTROL 2</b>	<b>REF</b> B4244-20 20 × → 1 mL				n/a
Ci-Trol <b>CONTROL 3</b>	<b>REF</b> B4244-30 20 × → 1 mL				n/a
<b>CONTROL N</b>	<b>REF</b> ORKE45 10 × → 1 mL				n/a
CA CLEAN I	<b>REF</b> 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
Thromborel® S	1 <sup>b</sup>	–	24
Ci-Trol <b>CONTROL 1</b>	Any position on sample rack	–	n/a
Ci-Trol <b>CONTROL 2</b>	Any position on sample rack	–	n/a
Ci-Trol <b>CONTROL 3</b>	Any position on sample rack	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

### Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	378
Hemoglobin	1 000
Bilirubin	12

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
PT seconds / Thromborel® S on CA-6000	$y = 1.00 x - 0.50 \text{ s}$	0.999

<sup>c</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol <b>CONTROL 3</b>	1.1	1.0	1.5
<b>CONTROL N</b>	0.7	0.7	0.9

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean	Median (s)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (s)
–	158	–	10.2	9.3 – 11.6

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.



## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	PT	STD-Link	No
Manage. ID <sup>d</sup>	5010		
Detector	for PT THS		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	180 sec		
Reag. Vol	PT THS	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>d</sup> The Management ID only applies to the CA-600 series.

## Standard Curve Calibration

The assay is not calibrated.

## Data Check

Special Menu – Settings – **Data Check**

– Mark Limits	Select Param.	PT
---------------	---------------	----

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

– Set Replication	Replicates	1
-------------------	------------	---



# Application Sheet

## PT INR / Thromborel® S

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	13
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Pro- tocol
Thromborel® S	<b>REF</b> OUHP53 10 x → 10 mL				PT THS
Ci-Trol <b>CONTROL 1</b>	<b>REF</b> B4244-10 20 x → 1 mL				n/a
Ci-Trol <b>CONTROL 2</b>	<b>REF</b> B4244-20 20 x → 1 mL				n/a
Ci-Trol <b>CONTROL 3</b>	<b>REF</b> B4244-30 20 x → 1 mL				n/a
<b>CONTROL N</b>	<b>REF</b> ORKE45 10 x → 1 mL				n/a
CA CLEAN I	<b>REF</b> 964-0631-3 1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
Thromborel® S	1 <sup>b</sup>	–	24
Ci-Trol <b>CONTROL 1</b>	Any position on sample rack	–	n/a
Ci-Trol <b>CONTROL 2</b>	Any position on sample rack	–	n/a
Ci-Trol <b>CONTROL 3</b>	Any position on sample rack	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

### Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	450
Hemoglobin	600
Bilirubin	36

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
PT INR / Thromborel® S on CA-6000	$y = 0.89x + 0.11^d$	0.999

<sup>c</sup> r = Correlation Coefficient

<sup>d</sup> no unit (INR)

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:

< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol CONTROL 3	1.0	0.9	1.3
CONTROL N	0.6	0.6	0.8

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

Not applicable.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	PT	STD-Link	No
Manage. ID <sup>e</sup>	5010		
Detector	for PT THS		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	180 sec		
Reag. Vol	PT THS	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

– Mark Limits	Select Param.	PT-INR
---------------	---------------	--------

## Remarks

System specific MNPT and ISI have to be used.

The mean normal PT (MNPT) is defined as the mean value of the normal range. Follow the appropriate CLSI guideline for establishing an MNPT.

ISI values for prothrombin time must be entered directly as they appear on the lot-specific table of ISI values. Any changes of the reagent lot, software (upgrades), major service, etc., require verification of the ISI value. Failure to enter the correct ISI value will cause incorrect International Normalization Ratio (INR) results.

For further information, please refer to the Instruction for Use of the reagent.

## Standard Curve Calibration

### Calibration Parameter 3

Standard Curve – Select Param.

Param.	PT-INR
Units	—
Number Format	XX.XX
Curve Fit	ISI Input

Standard Curve – Manual Entry

Enter the Normal seconds = MNPT and the ISI.

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---

### Siemens Healthineers Headquarters

Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



### Siemens Healthcare Diagnostics Products GmbH

Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**



# Application Sheet

## Derived Fibrinogen / Thromborel® S

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	14
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Pro- tocol
Thromborel® S	[REF] OUHP53 10 × → 10 mL				PT THS
Ci-Trol [CONTROL 2]	[REF] B4244-20 20 × → 1 mL				n/a
CA CLEAN I	[REF] 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	[REF] OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
Thromborel® S	1 <sup>b</sup>	–	24
Ci-Trol [CONTROL 2]	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

### Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	n/a <sup>c</sup>
Hemoglobin	100
Bilirubin	36

<sup>c</sup> Turbid samples are not suitable for Derived Fibrinogen determinations, as they may lead to abnormally low values. Interference of turbid samples may occur even if triglyceride concentrations are within the normal range. Any questionable result should be followed up with a more definitive quantitative method.

#### Limitations

Blood plasma substitutes that contain hydroxyethyl starch (HES) may interfere with the analysis. In a study with a HES solution (130/0.4) no interference was observed up to 6 g HES per liter plasma.

### Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

## Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
Fibrinogen / Dade® Thrombin Reagent on CA-500 series	$y = 1.00x - 0.10 \text{ g/L}$	0.870

<sup>d</sup> r = Correlation Coefficient

## Precision

The coefficient of variation of the analytical system (Within-Device CV) on the same lot of control plasma should be as follows:

< 10 %

	Mean (g/L)	Repeatability CV (%)	Within- Device/Lab CV (%)
Ci-Trol <b>CONTROL</b> 2	2.5	2.3	3.1
Normal plasma pool	2.7	1.6	1.9

## Measuring Range

Results within the measuring range/reference interval can be directly reported. Results outside the measuring range should be re-measured with a standard fibrinogen determination method (e.g., Fibrinogen with Dade® Thrombin Reagent or Fibrinogen with Multifibren® U).

## Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (g/L)	Median (g/L)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (g/L)	
-	124	2.8	2.7	1.9	- 4.0

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.



## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	PT	STD-Link	No
Manage. ID <sup>e</sup>	5010		
Detector	for PT THS		
End Point		50 %	
Maximum Time		100 sec	
Sensitivity	Low Gain		
Sample Vol		50 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		180 sec	
Reag. Vol	PT THS	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

– Mark Limits	Select Param.	dFbg
---------------	---------------	------

## Standard Curve (example only)

Verify the standard curve with the master curve provided with the PT reagent after each change of the reagent lot, and modify the standard curve if necessary.

dFbg

(g/L)	(dH)
1.9	62
4.0	144

## Standard Curve Calibration

Important!

The recommendation for the Number Format in Calibration Parameter differs from the information that is given in the Instructions for Use of the analyzer. Please check your Host System for correct interpretation of transmitted results whenever the Number Format will be changed.

### Calibration Parameter 4

Standard Curve – Select Param.

Param.	dFbg
Units	g/L or mg/dL
Number Format	XXX.X or XXXX
Curve Fit	—

Standard Curve – Manual Entry – Next (if applicable)

Enter the Derived Fibrinogen g/L or mg/dL concentrations and the dH of the Master Curve specified in the "Table of Assigned Values" of the specific Lot of the reagent used for the analyzer.

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---

### Siemens Healthineers Headquarters

Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



### Siemens Healthcare Diagnostics Products GmbH

Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**



# Application Sheet

## PT seconds / Dade® Innovin®

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	13
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

## Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
Dade® Innovin®	[REF] B4212-41 10 x → 4 mL	[REF] B4212-51 10 x → 10 mL	[REF] B4212-101 12 x → 20 mL		PT INN
Ci-Trol [CONTROL 1]	[REF] B4244-10 20 x → 1 mL				n/a
Ci-Trol [CONTROL 2]	[REF] B4244-20 20 x → 1 mL				n/a
Ci-Trol [CONTROL 3]	[REF] B4244-30 20 x → 1 mL				n/a
[CONTROL N]	[REF] ORKE45 10 x → 1 mL				n/a
CA CLEAN I	[REF] 964-0631-3 1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	[REF] OVKE03 10 pcs.				n/a

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
Dade® Innovin®	1 <sup>b</sup>	–	24
Ci-Trol [CONTROL 1]	Any position on sample rack	–	n/a
Ci-Trol [CONTROL 2]	Any position on sample rack	–	n/a
Ci-Trol [CONTROL 3]	Any position on sample rack	–	n/a
[CONTROL N]	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	373
Hemoglobin	1 000
Bilirubin	48

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
PT seconds / Dade® Innovin® on CA-6000	$y = 1.03 \times -0.26 \text{ s}$	0.999

<sup>c</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol CONTROL 3	0.9	1.5	1.8
CONTROL N	0.4	0.2	0.4

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean	Median (s)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (s)
–	158	–	10.2	9.3 – 11.4

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	PT	STD-Link	No
Manage. ID <sup>d</sup>	5110		
Detector	for PT INN		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	180 sec		
Reag. Vol	PT INN	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>d</sup> The Management ID only applies to the CA-600 series.

## Standard Curve Calibration

The assay is not calibrated.

## Data Check

Special Menu – Settings – **Data Check**

– Mark Limits	Select Param.	PT
---------------	---------------	----

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

– Set Replication	Replicates	1
-------------------	------------	---

## Remarks

As an alternative protocol it is admitted to extend the Maximum Time to 300 seconds if long coagulation times are expected.





# Application Sheet

## PT INR /

### Dade® Innovin®

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	14
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

## Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
Dade® Innovin®	[REF] B4212-41 10 x → 4 mL	[REF] B4212-51 10 x → 10 mL	[REF] B4212-101 12 x → 20 mL		PT INN
Ci-Trol [CONTROL 1]	[REF] B4244-10 20 x → 1 mL				n/a
Ci-Trol [CONTROL 2]	[REF] B4244-20 20 x → 1 mL				n/a
Ci-Trol [CONTROL 3]	[REF] B4244-30 20 x → 1 mL				n/a
[CONTROL N]	[REF] ORKE45 10 x → 1 mL				n/a
CA CLEAN I	[REF] 964-0631-3 1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	[REF] OVKE03 10 pcs.				n/a

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
Dade® Innovin®	1 <sup>b</sup>	–	24
Ci-Trol [CONTROL 1]	Any position on sample rack	–	n/a
Ci-Trol [CONTROL 2]	Any position on sample rack	–	n/a
Ci-Trol [CONTROL 3]	Any position on sample rack	–	n/a
[CONTROL N]	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	300
Hemoglobin	1 000
Bilirubin	60

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
PT INR / Dade® Innovin® on CA-6000	$y = 1.08x - 0.09^d$	0.999

<sup>c</sup> r = Correlation Coefficient

<sup>d</sup> no unit (INR)

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:

< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol <b>CONTROL 3</b>	0.9	1.6	1.8
<b>CONTROL N</b>	0.4	0.2	0.4

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

Not applicable.

### Bibliography

Refer to the Instructions for Use of the reagent.



## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	PT	STD-Link	No
Manage. ID <sup>e</sup>	5110		
Detector	for PT INN		
End Point		50 %	
Maximum Time		100 sec	
Sensitivity	Low Gain		
Sample Vol		50 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		180 sec	
Reag. Vol	PT INN	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

- Mark Limits	Select Param.	PT-INR
---------------	---------------	--------

## Remarks

System specific MNPT and ISI have to be used.

The mean normal PT (MNPT) is defined as the mean value of the normal range. Follow the appropriate CLSI guideline for establishing an MNPT.

ISI values for prothrombin time must be entered directly as they appear on the lot-specific table of ISI values. Any changes of the reagent lot, software (upgrades), major service, etc., require verification of the ISI value. Failure to enter the correct ISI value will cause incorrect International Normalization Ratio (INR) results.

As an alternative protocol it is admitted to extend the Maximum Time to 300 seconds if long coagulation times are expected.

For further information, please refer to the Instruction for Use of the reagent.

## Standard Curve Calibration

### Calibration Parameter 3

Standard Curve – Select Param.

Param.	PT-INR
Units	—
Number Format	XX.XX
Curve Fit	ISI Input

Standard Curve – Manual Entry – Next (if applicable)

Enter the Normal seconds = MNPT and the ISI.

## Number of Replicates

Special Menu – Settings – Analysis Settings

- Set Replication	Replicates	1
-------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

# Application Sheet

## Derived Fibrinogen / Dade® Innovin®

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	16
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
Dade® Innovin®	[REF] B4212-41 10 x → 4 mL	[REF] B4212-51 10 x → 10 mL	[REF] B4212-101 12 x → 20 mL		PT INN
Ci-Trol [CONTROL 2]	[REF] B4244-20 20 x → 1 mL				n/a
CA CLEAN I	[REF] 964-0631-3 1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	[REF] OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
Dade® Innovin®	1 <sup>b</sup>	–	24
Ci-Trol [CONTROL 2]	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

### Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	n/a <sup>c</sup>
Hemoglobin	100
Bilirubin	36

<sup>c</sup> Turbid samples are not suitable for Derived Fibrinogen determinations, as they may lead to abnormally low values. Interference of turbid samples may occur even if triglyceride concentrations are within the normal range. Any questionable result should be followed up with a more definitive quantitative method.

#### Limitations

Blood plasma substitutes that contain hydroxyethyl starch (HES) may interfere with the analysis. In a study with a HES solution (130/0.4) no interference was observed up to 3 g HES per liter plasma.

### Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

## Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
Fibrinogen / Dade® Thrombin Reagent on CA-500 series	$y = 1.25x - 0.58 \text{ g/L}$	0.857

<sup>d</sup> r = Correlation Coefficient

## Precision

The coefficient of variation of the analytical system (Within-Device CV) on the same lot of control plasma should be as follows:

< 10 %

	Mean (g/L)	Repeatability CV (%)	Within- Device/Lab CV (%)
Ci-Trol <b>CONTROL 2</b>	2.7	2.9	3.3
Normal plasma pool	3.0	2.4	4.1

## Measuring Range

Results within the measuring range/reference interval can be directly reported. Results outside the measuring range should be re-measured with a standard fibrinogen determination method (e.g., Fibrinogen with Dade® Thrombin Reagent or Fibrinogen with Multifibren® U).

## Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (g/L)	Median (g/L)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (g/L)
–	123	2.9	2.8	2.0 – 4.2

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	PT	STD-Link	No
Manage. ID <sup>e</sup>	5110		
Detector	for PT INN		
End Point		50 %	
Maximum Time		100 sec	
Sensitivity	Low Gain		
Sample Vol		50 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		180 sec	
Reag. Vol	PT INN	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

– Mark Limits	Select Param.	dFbg
---------------	---------------	------

## Standard Curve (example only)

Verify the standard curve with the master curve provided with the PT reagent after each change of the reagent lot, and modify the standard curve if necessary.

dFbg

(g/L)	(dH)
2.0	43
4.2	84

## Standard Curve Calibration

Important!

The recommendation for the Number Format in Calibration Parameter differs from the information that is given in the Instructions for Use of the analyzer. Please check your Host System for correct interpretation of transmitted results whenever the Number Format will be changed.

### Calibration Parameter 4

Standard Curve – Select Param.

Param.	dFbg
Units	g/L or mg/dL
Number Format	XXX.X or XXXX
Curve Fit	—

Standard Curve – Manual Entry – Next (if applicable)

Enter the Derived Fibrinogen g/L or mg/dL concentrations and the dH of the Master Curve specified in the "Table of Assigned Values" of the specific Lot of the reagent used for the analyzer.

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---

### Siemens Healthineers Headquarters

Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



### Siemens Healthcare Diagnostics Products GmbH

Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**



## ■ APTT





## Application Sheet

# APTT /

# Dade® Actin® Activated Cephaloplastin Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

Version	14
Release Date	2024-04
Software Version	≥ 00-17 <sup>a</sup>
USA only	

<sup>a</sup> CA-620,  
CA-660

## Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
<b>ACTIN</b>	<b>REF</b> B4218-1 10 × 2 mL	<b>REF</b> B4218-2 10 × 10 mL			PTT ACT
Ci-Trol <b>CONTROL 1</b>	<b>REF</b> B4244-10 20 × → 1 mL				n/a
Ci-Trol <b>CONTROL 2</b>	<b>REF</b> B4244-20 20 × → 1 mL				n/a
Ci-Trol <b>CONTROL 3</b>	<b>REF</b> B4244-30 20 × → 1 mL				n/a
<b>CONTROL N</b>	<b>REF</b> ORKE45 10 × → 1 mL				n/a
CaCl <sub>2</sub> <b>SOLUTION</b>	<b>REF</b> ORHO37 10 × 15 mL				CaCl <sub>2</sub>
CA CLEAN I	<b>REF</b> 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03 10 pcs.				n/a
BC Vial Kit (empty vials for 15 mL)	<b>REF</b> OVKE05 10 pcs.				n/a

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
<b>ACTIN</b>	2 <sup>b</sup> any non-cooled reagent position	–	48 24
Ci-Trol <b>CONTROL 1</b>	Any position on sample rack	–	n/a
Ci-Trol <b>CONTROL 2</b>	Any position on sample rack	–	n/a
Ci-Trol <b>CONTROL 3</b>	Any position on sample rack	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
CaCl <sub>2</sub> <b>SOLUTION</b>	7 <sup>c</sup>	–	48
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	337
Hemoglobin	40
Bilirubin	12

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
APTT / Dade® Actin® Activated Cephaloplastin Reagent on CA-6000	$y = 1.00x - 0.20s$	0.982

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol <b>CONTROL 3</b>	0.6	1.3	1.4
<b>CONTROL N</b>	1.0	3.4	3.5

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (s)	Median (s)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (s)
–	111	25.7	25.6	21.4 – 30.6

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	APTT	STD-Link	No
Manage. ID <sup>e</sup>	5200		
Detector	for PTT ACT		
End Point	50 %		
Maximum Time	190 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		60 sec	
Reag. Vol	PTT ACT	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		240 sec	
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	APTT
---------------	---------------	------

## Standard Curve Calibration

The assay is not calibrated.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---





## Application Sheet

# APTT /

# Dade® Actin® FS Activated PTT Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	14
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

## Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
ACTIN FS	REF B4218-20 10 × 2 mL	REF B4218-100 10 × 10 mL			PTT FS
Ci-Trol CONTROL 1	REF B4244-10 20 × → 1 mL				n/a
Ci-Trol CONTROL 2	REF B4244-20 20 × → 1 mL				n/a
Ci-Trol CONTROL 3	REF B4244-30 20 × → 1 mL				n/a
CONTROL N	REF ORKE45 10 × → 1 mL				n/a
CaCl <sub>2</sub> SOLUTION	REF ORHO37 10 × 15 mL				CaCl <sub>2</sub>
CA CLEAN I	REF 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	REF OVKE03 10 pcs.				n/a

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
ACTIN FS	2 <sup>b</sup>	–	48
	any non-cooled reagent position	–	24
Ci-Trol CONTROL 1	Any position on sample rack	–	n/a
Ci-Trol CONTROL 2	Any position on sample rack	–	n/a
Ci-Trol CONTROL 3	Any position on sample rack	–	n/a
CONTROL N	Any position on sample rack	–	n/a
CaCl <sub>2</sub> SOLUTION	7 <sup>c</sup>	–	48
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	331
Hemoglobin	1 000
Bilirubin	6

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
APTT / Dade® Actin® FS Activated PTT Reagent on CA-6000	$y = 1.00 x + 0.10 s$	0.983

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol CONTROL 3	0.3	1.5	1.5
CONTROL N	0.5	0.2	0.5

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (s)	Median (s)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (s)
–	111	24.8	24.6	21.8 – 28.0

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	APTT	STD-Link	No
Manage. ID <sup>e</sup>	5210		
Detector	for PTT FS		
End Point	50 %		
Maximum Time	190 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	60 sec		
Reag. Vol	PTT FS	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	240 sec		
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	APTT
---------------	---------------	------

## Standard Curve Calibration

The assay is not calibrated.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---





## Application Sheet

# APTT /

# Dade® Actin® FSL Activated PTT Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

Version	14
Release Date	2024-04
Software Version	≥ 00-17 <sup>a</sup>
USA only	

<sup>a</sup> CA-620,  
CA-660

## Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
ACTIN FSL	[REF] B4219-1 10 × 2 mL	[REF] B4219-2 10 × 10 mL			PTT FSL
Ci-Trol CONTROL 1	[REF] B4244-10 20 × → 1 mL				n/a
Ci-Trol CONTROL 2	[REF] B4244-20 20 × → 1 mL				n/a
Ci-Trol CONTROL 3	[REF] B4244-30 20 × → 1 mL				n/a
CONTROL N	[REF] ORKE45 10 × → 1 mL				n/a
CaCl <sub>2</sub> SOLUTION	[REF] ORHO37 10 × 15 mL				CaCl <sub>2</sub>
CA CLEAN I	[REF] 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	[REF] OVKE03 10 pcs.				n/a

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
ACTIN FSL	2 <sup>b</sup>	–	48
	any non-cooled reagent position	–	24
Ci-Trol CONTROL 1	Any position on sample rack	–	n/a
Ci-Trol CONTROL 2	Any position on sample rack	–	n/a
Ci-Trol CONTROL 3	Any position on sample rack	–	n/a
CONTROL N	Any position on sample rack	–	n/a
CaCl <sub>2</sub> SOLUTION	7 <sup>c</sup>	–	48
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	331
Hemoglobin	200
Bilirubin	12

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
APTT / Dade® Actin® FSL Activated PTT Reagent on CA-6000	$y = 1.00 x + 0.10 s$	0.990

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol CONTROL 3	0.4	1.4	1.5
CONTROL N	0.4	0.2	0.4

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (s)	Median (s)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (s)
–	111	27.9	27.7	24.5 – 32.8

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	APTT	STD-Link	No
Manage. ID <sup>e</sup>	5220		
Detector	for PTT FSL		
End Point	50 %		
Maximum Time	190 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D. Samp Vol	0 µL		
Dil. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	60 sec		
Reag. Vol	PTT FSL	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	240 sec		
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Standard Curve Calibration

The assay is not calibrated.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	APTT
---------------	---------------	------

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---

## Remarks

As an alternative protocol it is admitted to extend the Maximum Time to 300 seconds if long coagulation times are expected.

According to troubleshooting instructions (CA series Measurement Evaluation and Check Methods), the Maximum Time can be extended to 600 seconds, if an Analysis Time Over error still persists with the measurement.





# Application Sheet

## APTT / Pathromtin® SL

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	15
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
Pathromtin® SL	[REF] OQGS29 10 × 5 mL	[REF] OQGS35 20 × 5 mL			PTT PSL
Ci-Trol [CONTROL 1]	[REF] B4244-10 20 × → 1 mL				n/a
Ci-Trol [CONTROL 2]	[REF] B4244-20 20 × → 1 mL				n/a
Ci-Trol [CONTROL 3]	[REF] B4244-30 20 × → 1 mL				n/a
[CONTROL N]	[REF] ORKE45 10 × → 1 mL				n/a
CaCl <sub>2</sub> [SOLUTION]	[REF] ORHO37 10 × 15 mL				CaCl <sub>2</sub>
CA CLEAN I	[REF] 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	[REF] OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

The reagent must be gently inverted (5 to 8 times) to mix before first use.

### On-board Stability

Component	Position	Condition	Time (h)
Pathromtin® SL	2 <sup>b</sup> any non-cooled reagent position	–	48 24
Ci-Trol [CONTROL 1]	Any position on sample rack	–	n/a
Ci-Trol [CONTROL 2]	Any position on sample rack	–	n/a
Ci-Trol [CONTROL 3]	Any position on sample rack	–	n/a
[CONTROL N]	Any position on sample rack	–	n/a
CaCl <sub>2</sub> [SOLUTION]	7 <sup>c</sup>	–	48
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	378
Hemoglobin	200
Bilirubin	2.4

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
APTT / Pathromtin® SL on CA-6000	$y = 0.99x - 1.10s$	0.968

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 5 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol CONTROL 1	0.6	1.2	1.3
Ci-Trol CONTROL 2	0.9	2.4	2.5

### Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (s)	Median (s)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (s)
–	110	34.1	33.8	29.0 – 40.2

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	APTT	STD-Link	No
Manage. ID <sup>e</sup>	5230		
Detector	for PTT PSL		
End Point	50 %		
Maximum Time	190 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	30 sec		
Reag. Vol	PTT PSL	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	150 sec		
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	APTT
---------------	---------------	------

## Standard Curve Calibration

The assay is not calibrated.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---





## ■ Fibrinogen



# Application Sheet

## Fibrinogen / Multifibren® U

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	15
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product	Order No.	Order No.	Order No.	Order No.	Name in Test Protocol
• Component(s)	Package Size 1	Package Size 2	Package Size 3	Package Size 4	
Multifibren® U	[REF] OWZG19 10 x → 2 mL	[REF] OWZG23 10 x → 5 mL			Fbg MFU
[FIBRINOGEN] [CALIBRATOR]	[REF] OQVK11				
• [CALIBRATOR 1] <sup>b</sup>	1 x → 1 mL				Calibrator 1
• [CALIBRATOR 2]	1 x → 1 mL				Calibrator 2
• [CALIBRATOR 3]	1 x → 1 mL				Calibrator 3
• [CALIBRATOR 4]	1 x → 1 mL				Calibrator 4
• [CALIBRATOR 5]	1 x → 1 mL				Calibrator 5
• [CALIBRATOR 6]	1 x → 1 mL				Calibrator 6
Ci-Trol [CONTROL 1]	[REF] B4244-10 20 x → 1 mL				n/a
[CONTROL N]	[REF] ORKE45 10 x → 1 mL				n/a
CA CLEAN I	[REF] 964-0631-3 1 x 50 mL				Clean I

<sup>b</sup> [CALIBRATOR 1] is not used in this test.

### Additional Notes

The required controls and calibrators have to be transferred into appropriate sample cups.

CA CLEAN I has to be transferred into an appropriate vial.

### On-board Stability

Component	Position	Condition	Time (h)
Multifibren® U	3 <sup>c</sup>	–	24
[CALIBRATOR 1]	n/a <sup>d</sup>	–	n/a
[CALIBRATOR 2]	#1	–	n/a
[CALIBRATOR 3]	#2	–	n/a
[CALIBRATOR 4]	#3	–	n/a
[CALIBRATOR 5]	#4	–	n/a
[CALIBRATOR 6]	#5	–	n/a
Ci-Trol [CONTROL 1]	Any position on sample rack	–	n/a
[CONTROL N]	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>c</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>d</sup> [CALIBRATOR 1] is not used in this test.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	284
Hemoglobin	800
Bilirubin	36

### Limitations

Blood plasma substitutes that contain hydroxyethyl starch (HES) may interfere with the analysis. In a study with a HES solution (130/0.4) no interference was observed up to 3 g HES per liter plasma.

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>e</sup>
Fibrinogen / Multifibren® U on BCT	$y = 1.01x - 0.28 \text{ g/L}$	0.973

<sup>e</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 10 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
<b>CONTROL N</b>	4.5	3.1	5.3
Pathological plasma pool low	3.5	1.4	3.6

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (g/L)	Median (g/L)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (g/L)
–	124	2.6	2.6	1.9 – 3.5

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	Fbg	STD-Link	No
Manage. ID <sup>f</sup>	5360		
Detector	for Fbg		
End Point	30 %		
Maximum Time	100 sec		
Sensitivity	Low Gain		
Sample Vol	100 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	60 sec		
Reag. Vol	Fbg MFU	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>f</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

– Mark Limits	Select Param.	Fbg.C	
– Report Limits	lower (<)	1.1 g/L	or 110 mg/dL
	upper (>)	8.0 g/L	or 800 mg/dL

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

Fbg.C

(g/L)	(s)
8.0	7.3
5.4	8.5
3.5	11.4
2.4	14.4
1.1	25.6

## Remarks

**CALIBRATOR 1** is not used in this test.

## Standard Curve Calibration

Important!

The recommendation for the Number Format in Calibration Parameter differs from the information that is given in the Instructions for Use of the analyzer. Please check your Host System for correct interpretation of transmitted results whenever the Number Format will be changed.

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	Fbg.C
Units	g/L or mg/dL
Number Format	XXX.X or XXXX
Curve Fit	Log Curve

Standard Curve – Standard Analysis

Select Dilution Set	M
Calibrator	Fib. Calibrator Kit

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	Calibrator 2	2
Calib. or Dil.Ratio 2	Calibrator 3	2
Calib. or Dil.Ratio 3	Calibrator 4	2
Calib. or Dil.Ratio 4	Calibrator 5	2
Calib. or Dil.Ratio 5	Calibrator 6	2
Calib. or Dil.Ratio 6	—	—

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

# Application Sheet Fibrinogen / Dade® Thrombin Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	14
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

## Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
THROMBIN REAGENT	REF B4233-25 10 × → 1 mL	REF B4233-27 10 × → 5 mL			Fbg
FIBRINOGEN DETERMINATION	REF B4233-17SY				
• THROMBIN REAGENT	6 × 1 mL				Fbg
• FIBRINOGEN STANDARD	1 × → 1 mL				n/a
• OV BUFFER	3 × 15 mL				OVB
Ci-Trol CONTROL 1	REF B4244-10 20 × → 1 mL				n/a
CONTROL P	REF OUPZ19 10 × → 1 mL				n/a
Data-Fi FIBRINOGEN CONTROL	REF B4233-22 10 × → 1 mL				n/a
STANDARD PLASMA	REF ORKL19 10 × → 1 mL				SHP
CA SYSTEM BUFFER	REF B4265-37 8 × 250 mL				OVB
OV BUFFER	REF B4234-25 10 × 15 mL				OVB
CA CLEAN I	REF 964-0631-3 1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	REF OVKE03 10 pcs.				n/a

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
THROMBIN REAGENT	3 <sup>b</sup>	–	24
THROMBIN REAGENT	Any position on reagent rack	–	24
FIBRINOGEN STANDARD	#1	–	n/a
OV BUFFER	Buffer position 12	GW5; SLD Vial	8
Ci-Trol CONTROL 1	Any position on sample rack	–	n/a
CONTROL P	Any position on sample rack	–	n/a
Data-Fi FIBRINOGEN CONTROL	Any position on sample rack	–	n/a
STANDARD PLASMA	#1	–	n/a

Component	Position	Condition	Time (h)
CA SYSTEM   BUFFER	Buffer position 12	GW 5; SLD Vial <sup>c</sup>	8
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> For positioning on the analyzer, the buffer has to be transferred into an appropriate vial.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	341
Hemoglobin	1 000
Bilirubin	48

### Limitations

If samples are measured in a 1:5 dilution, any presence of elevated triglycerides or any other turbidity in the sample may interfere the analysis.

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
Fibrinogen / Dade® Thrombin Reagent on CA-1500	$y = 1.05x + 0.04 \text{ g/L}$	0.974

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 10 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
Ci-Trol   CONTROL   1	1.9	4.1	4.6
Data-Fi   FIBRINOGEN   CONTROL	3.8	3.0	4.8

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (g/L)	Median (g/L)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (g/L)
–	123	2.73	2.70	2.10 – 3.58

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.



## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	Fbg	STD-Link	Master
Manage. ID <sup>e</sup>	5300		
Detector	for Fbg		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	High Gain		
Sample Vol	10 µL		
Dil.Vol	OVB	90 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	60 sec		
Reag. Vol	Fbg	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

All samples exceeding the mentioned report limits should be repeated using the appropriate +Fbg or -Fbg setting again. The redilution has to be requested manually.

Special Menu – Settings – Data Check

– Mark Limits	Select Param.	Fbg.C	
– Report Limits	lower (<)	1.00 g/L	or 100 mg/dL
	upper (>)	4.50 g/L	or 450 mg/dL

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

Fbg.C

(g/L)	(s)
5.20	5.5
3.90	6.7
2.60	9.6
1.30	19.2
0.87	34.1

## Standard Curve Calibration

Important!

The recommendation for the Number Format in Calibration Parameter differs from the information that is given in the Instructions for Use of the analyzer. Please check your Host System for correct interpretation of transmitted results whenever the Number Format will be changed.

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	Fbg.C
Units	g/L or mg/dL
Number Format	XX.XX or XXXX
Curve Fit	Log Curve

Standard Curve – Standard Analysis

Select Dilution Set	9
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	2/1	2
Calib. or Dil.Ratio 2	3/2	2
Calib. or Dil.Ratio 3	1/1	2
Calib. or Dil.Ratio 4	1/2	2
Calib. or Dil.Ratio 5	1/3	2
Calib. or Dil.Ratio 6	0/1	0

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	+Fbg	STD-Link	Fbg
Manage. ID <sup>f</sup>	5310		
Detector	for Fbg		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	High Gain		
Sample Vol	5 µL		
Dil.Vol	OVB	95 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
Reagent 1	60 sec		
Reag. Vol	Fbg	50 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	Clean I	x 1	
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	

<sup>f</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	+Fbg	
- Report Limits	lower (<)	1.80 g/L	or 180 mg/dL
	upper (>)	9.00 g/L	or 900 mg/dL

## Standard Curve Calibration

Not applicable - Standard curve created with "Fbg" will be used automatically. For more information refer to the Instructions for Use of the Analyzer.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	-Fbg	STD-Link	Fbg
Manage. ID <sup>9</sup>	5320		
Detector	for Fbg		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	High Gain		
Sample Vol	20 µL		
Dil.Vol	OVB	80 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
Reagent 1	60 sec		
Reag. Vol	Fbg	50 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	Clean I	x 1	
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	

<sup>9</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	-Fbg	
- Report Limits	lower (<)	0.50 g/L	or 50 mg/dL
	upper (>)	2.50 g/L	or 250 mg/dL

## Standard Curve Calibration

Not applicable - Standard curve created with "Fbg" will be used automatically. For more information refer to the Instructions for Use of the Analyzer.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1





## ■ Thrombin Time/Batroxobin Time



# Application Sheet

## Thrombin time / Test Thrombin Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	13
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
TEST THROMBIN	REF OWHM13				
• TEST THROMBIN REAGENT	10 × → 5 mL				TestThr
• TEST THROMBIN REAGENT DILUENT	1 × 50 mL				n/a
CONTROL N	REF ORKE45				
	10 × → 1 mL				n/a
CA CLEAN I	REF 964-0631-3				
	1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	REF OVKE03				
	10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls have to be transferred into appropriate sample cups.

#### Limitations

If the Thrombin Time is longer than the reference interval, determine the fibrinogen concentration. Report Thrombin Time if the fibrinogen concentration is below or equal to 7 g/L. Do not report the Thrombin Time if the fibrinogen concentration is higher than 7 g/L.

### On-board Stability

Component	Position	Condition	Time (h)
TEST THROMBIN REAGENT	2 <sup>b</sup>	–	24
TEST THROMBIN REAGENT DILUENT	n/a	–	n/a
CONTROL N	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

### Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	341
Hemoglobin	20
Bilirubin	24

### Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

## Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
TT / Test Thrombin Reagent on BFA	$y = 0.56 x + 5.69 s$	0.946

<sup>c</sup> r = Correlation Coefficient

## Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:

< 10 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
CONTROL N	6.2	3.9	7.0

## Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

## Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (s)	Median (s)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (s)
-	180	17.8	17.9	16.1 – 19.5

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.



## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	TT	STD-Link	No
Manage. ID <sup>d</sup>	5330		
Detector	for TT		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	60 sec		
Reag. Vol	TestThr	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>d</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	TT
---------------	---------------	----

## Standard Curve Calibration

The assay is not calibrated.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---



# Application Sheet

## Batroxobin time / Batroxobin Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	12
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
Batroxobin <b>REAGENT</b>	<b>REF</b> OUOV21 2 × → 5 mL				Batrox
<b>CONTROL I</b>	<b>REF</b> ORKE45 10 × → 1 mL				n/a
CA CLEAN I	<b>REF</b> 964-0631-3 1 × 50 mL				Clean I

### Additional Notes

The required controls have to be transferred into appropriate sample cups.

CA CLEAN I has to be transferred into an appropriate vial.

### On-board Stability

Component	Position	Condition	Time (h)
Batroxobin <b>REAGENT</b>	4 <sup>b</sup>	–	48
<b>CONTROL I</b>	Any position on sample rack	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

### Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	600
Hemoglobin	1 000
Bilirubin	12

### Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
Batroxobin time / Batroxobin Reagent on BCT	$y = 0.77x + 5.66$	0.984

<sup>c</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 10 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
<b>CONTROL N</b>	1.0	1.2	1.5
Pathological plasma pool	1.9	0.7	1.9

## Measuring Range

Refer to the Instructions for Use of the analyzer for additional information.

## Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (s)	Median (s)	5 <sup>th</sup> to 95 <sup>th</sup> percentile (s)
–	66	17.6	17.6	16.7 – 18.9

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	BXT	STD-Link	No
Manage. ID <sup>d</sup>	5350		
Detector	for BXT		
End Point	50 %		
Maximum Time	100 sec		
Sensitivity	Low Gain		
Sample Vol	50 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	60 sec		
Reag. Vol	Batrox	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 3	0 sec		
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>d</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – **Data Check**

– <b>Mark Limits</b>	Select Param.	BXT
----------------------	---------------	-----

## Standard Curve Calibration

The assay is not calibrated.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

– <b>Set Replication</b>	Replicates	1
--------------------------	------------	---





## ■ Clotting Assays





# Application Sheet

## Coagulation Factor VII / Dade® Innovin®

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	13
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
<b>FACTOR VII</b> <b>DEFICIENT</b>	<b>REF</b> OTXV13 3 x → 1 mL				VII
Dade® Innovin®	<b>REF</b> B4212-41 10 x → 4 mL	<b>REF</b> B4212-51 10 x → 10 mL	<b>REF</b> B4212-101 12 x → 20 mL		PT INN
<b>STANDARD PLASMA</b>	<b>REF</b> ORKL19 10 x → 1 mL				SHP
<b>CONTROL N</b>	<b>REF</b> ORKE45 10 x → 1 mL				n/a
<b>CONTROL P</b>	<b>REF</b> OUPZ19 10 x → 1 mL				n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	<b>REF</b> B4265-37 8 x 250 mL				OVB
<b>OV</b> <b>BUFFER</b>	<b>REF</b> B4234-25 10 x 15 mL				OVB
CA CLEAN I	<b>REF</b> 964-0631-3 1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
<b>FACTOR VII</b> <b>DEFICIENT</b>	6 <sup>b</sup>	–	8
Dade® Innovin®	1 <sup>c</sup>	–	24
<b>STANDARD PLASMA</b>	#1	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
<b>CONTROL P</b>	Any position on sample rack	–	n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	Buffer position 12	–	n/a
<b>OV</b> <b>BUFFER</b>	Buffer position 12	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

<sup>c</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	3 000
Hemoglobin	1 000
Bilirubin	36

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
Coagulation Factor VII / Thromborel® S on BCT	$y = 0.97x - 1.55\%$ of Norm	0.976

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 15 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
CONTROL N	5.0	1.3	4.9
CONTROL P	3.9	1.8	4.1

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

Refer to the **FACTOR VII DEFICIENT** Instructions for Use.

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

<b>Test Protocol Name</b>	VII	<b>STD-Link</b>	No
<b>Manage. ID<sup>e</sup></b>	5410		
Detector	for F-Ext <sup>f</sup>		
End Point		50 %	
Maximum Time		100 sec	
Sensitivity	Low Gain		
Sample Vol		5 µL	
Dil.Vol	OVB	45 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	VII	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		90 sec	
Reag. Vol	PT INN	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

<sup>f</sup> For the CA-600 series, it is also possible to select the detector "for FExtINN".

## Data Check

Special Menu – Settings – Data Check

<b>– Mark Limits</b>	Select Param.	VII %
----------------------	---------------	-------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

VII %

(%)	(s)
139.5	17.0
93.0	20.1
46.5	26.7
23.3	36.9
11.6	54.4

## Remarks

Important!

The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have to be entered by the service only. Please contact your local service.

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	VII %
Units	%
Number Format	XXX.X
Curve Fit	Log Curve

Standard Curve – Standard Analysis

Select Dilution Set	8
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	3/2	2
Calib. or Dil.Ratio 2	1/1	2
Calib. or Dil.Ratio 3	1/2	2
Calib. or Dil.Ratio 4	1/4	2
Calib. or Dil.Ratio 5	1/8	2
Calib. or Dil.Ratio 6	0/1	0

## Number of Replicates

Special Menu – Settings – Analysis Settings

<b>– Set Replication</b>	Replicates	1
--------------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

# Application Sheet

## Coagulation Factor VIII / Dade® Actin® FSL Activated PTT Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	13
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
FACTOR VIII DEFICIENT	REF OTXW17 8 x → 1 mL				VIII
ACTIN FSL	REF B4219-1 10 x 2 mL	REF B4219-2 10 x 10 mL			PTT FSL
STANDARD PLASMA	REF ORKL19 10 x → 1 mL				SHP
CONTROL N	REF ORKE45 10 x → 1 mL				n/a
CONTROL P	REF OUPZ19 10 x → 1 mL				n/a
CaCl <sub>2</sub> SOLUTION	REF ORHO37 10 x 15 mL				CaCl <sub>2</sub>
CA SYSTEM BUFFER	REF B4265-37 8 x 250 mL				OVB
OV BUFFER	REF B4234-25 10 x 15 mL				OVB
CA CLEAN I	REF 964-0631-3 1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	REF OVKE03 10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
FACTOR VIII DEFICIENT	8 <sup>b</sup>	–	4
ACTIN FSL	2 <sup>c</sup>	–	48
STANDARD PLASMA	#1	–	n/a
CONTROL N	Any position on sample rack	–	n/a
CONTROL P	Any position on sample rack	–	n/a
CaCl <sub>2</sub> SOLUTION	7 <sup>d</sup>	–	48
CA SYSTEM BUFFER	Buffer position 12	–	n/a

Component	Position	Condition	Time (h)
OV   BUFFER	Buffer position 12	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other non-cooled reagent position can be used.

<sup>c</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>d</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	3 000
Hemoglobin	40
Bilirubin	24

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>e</sup>
Coagulation Factor VIII / Pathromtin® SL on BCT	$y = 1.00 \times + 3.71 \% \text{ of Norm}$	0.960

<sup>e</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:

< 15 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
CONTROL N	2.5	3.2	4.0
CONTROL P	3.2	4.2	5.2

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

Refer to the FACTOR VIII DEFICIENT Instructions for Use.

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

<b>Test Protocol Name</b>	VIII	<b>STD-Link</b>	No
<b>Manage. ID<sup>f</sup></b>	5430		
Detector	for F-Int <sup>g</sup>		
End Point	50 %		
Maximum Time	150 sec		
Sensitivity	Low Gain		
Sample Vol	5 µL		
Dil.Vol	OVB	45 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1	30 sec		
Reag. Vol	VIII	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2	60 sec		
Reag. Vol	PTT FSL	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3	240 sec		
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1

<sup>f</sup> The Management ID only applies to the CA-600 series.

<sup>g</sup> For the CA-600 series, it is also possible to select the detector "for FlntACT".

## Data Check

Special Menu – Settings – **Data Check**

<b>– Mark Limits</b>	Select Param.	VIII %
----------------------	---------------	--------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

VIII %

(%)	(s)
129.0	66.7
86.0	72.1
43.0	82.2
21.5	92.9
10.8	104.0

## Standard Curve Calibration

For higher concentrations (approx. 150 to 12.5 %) select Dilution Set 8.

### Calibration Parameter 1

Standard Curve – **Select Param.**

Param.	VIII %
Units	%
Number Format	XXX.X
Curve Fit	Log Curve

Standard Curve – **Standard Analysis**

Select Dilution Set	8
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	3/2	2
Calib. or Dil.Ratio 2	1/1	2
Calib. or Dil.Ratio 3	1/2	2
Calib. or Dil.Ratio 4	1/4	2
Calib. or Dil.Ratio 5	1/8	2
Calib. or Dil.Ratio 6	0/1	0

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

<b>– Set Replication</b>	Replicates	1
--------------------------	------------	---

## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	VIII	STD-Link	No
Manage. ID <sup>h</sup>	5430		
Detector	for F-Int <sup>i</sup>		
End Point	50 %		
Maximum Time	150 sec		
Sensitivity	Low Gain		
Sample Vol	5 µL		
Dil.Vol	OVB	45 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	VIII	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		60 sec	
Reag. Vol	PTT FSL	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		240 sec	
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1

<sup>h</sup> The Management ID only applies to the CA-600 series.

<sup>i</sup> For the CA-600 series, it is also possible to select the detector "for FlntACT".

## Data Check

Special Menu – Settings – **Data Check**

- Mark Limits	Select Param.	VIII %
---------------	---------------	--------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

VIII %

(%)	(s)
86.0	70.2
43.0	79.9
21.5	89.7
10.8	100.3
5.4	110.2
2.7	118.7

## Remarks

Important!

## Standard Curve Calibration

For lower concentrations (approx. 100 to 3.1 %) select Dilution Set 1.

### Calibration Parameter 1

Standard Curve – **Select Param.**

Param.	VIII %
Units	%
Number Format	XXX.X
Curve Fit	Log Curve

Standard Curve – **Standard Analysis**

Select Dilution Set	1
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	1/1	2
Calib. or Dil.Ratio 2	1/2	2
Calib. or Dil.Ratio 3	1/4	2
Calib. or Dil.Ratio 4	1/8	2
Calib. or Dil.Ratio 5	1/16	2
Calib. or Dil.Ratio 6	1/32	2

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---



The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have to be entered by the service only. Please contact your local service.

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**



# Application Sheet

## Protein C / Protein C Reagent

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	13
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-620,  
CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
<b>PROTEIN C COAG</b>	<b>REF</b> OQYG11				
• <b>PROTEIN C COAG</b> <b>ACTIVATOR</b>	1 x → 3 mL				PC.A.cl
• <b>PROTEIN C COAG</b> <b>REAGENT</b> <b>APTT</b>	1 x 10 mL				PC.APTT
• <b>PROTEIN C COAG</b> <b>DEFICIENT</b>	4 x → 1 mL				PC.DefP
<b>STANDARD PLASMA</b>	<b>REF</b> ORKL19				
	10 x → 1 mL				SHP
<b>CONTROL N</b>	<b>REF</b> ORKE45				
	10 x → 1 mL				n/a
<b>CONTROL P</b>	<b>REF</b> OUPZ19				
	10 x → 1 mL				n/a
CaCl <sub>2</sub> <b>SOLUTION</b>	<b>REF</b> ORHO37				
	10 x 15 mL				CaCl <sub>2</sub>
CA CLEAN I	<b>REF</b> 964-0631-3				
	1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03				
	10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
<b>PROTEIN C COAG</b> <b>ACTIVATOR</b>	1 <sup>b</sup>	–	24
<b>PROTEIN C COAG</b> <b>REAGENT</b> <b>APTT</b>	2 <sup>b</sup>	–	24
<b>PROTEIN C COAG</b> <b>DEFICIENT</b>	10	–	6
<b>STANDARD PLASMA</b>	#1	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
<b>CONTROL P</b>	Any position on sample rack	–	n/a
CaCl <sub>2</sub> <b>SOLUTION</b>	7 <sup>c</sup>	–	24
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position (positions Reagent holder position 5 to 10) can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	3012
Hemoglobin	600
Bilirubin	36

### Limitations

Hemolyzed samples are not suitable for protein C determination.

Higher levels of lipids or turbid samples can lead to falsely elevated or decreased values.

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
Protein C / Protein C Reagent on BCT (coagulometric)	$y = 1.01x + 3.60\%$ of Norm	0.989

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:

< 15 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
CONTROL N	1.9	4.3	4.7
CONTROL P	2.5	4.5	5.1

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

Refer to the Instructions for Use of the reagent.

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	PCcl	STD-Link	No
Manage. ID <sup>e</sup>	5500		
Detector	for PCc		
End Point	50 %		
Maximum Time	300 sec		
Sensitivity	Low Gain		
Sample Vol	5 µL		
Dil.Vol	PC.DefP	45 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
2nd Dil			
D.Samp Vol	0 µL		
Dil.Vol	*****	0 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	*****	x 0	
Reagent 1	30 sec		
Reag. Vol	PC.A.cl	50 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	Clean I	x 1	
Reagent 2	60 sec		
Reag. Vol	PC.APTT	50 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	Clean I	x 1	
Reagent 3	300 sec		
Reag. Vol	CaCl2	50 µL	
Pre. Rinse	*****	x 0	
Post. Rinse	Clean I	x 1	

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

- Mark Limits	Select Param.	PC.cl %
---------------	---------------	---------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

PC.cl%

(%)	(s)
148.5	115.5
99.0	91.7
49.5	66.8
24.8	50.0
12.4	41.3
0.0	34.3

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	PC.cl %
Units	%
Number Format	XXX.X
Curve Fit	Lin-Lin

Standard Curve – Standard Analysis

Select Dilution Set	8
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	3/2	2
Calib. or Dil.Ratio 2	1/1	2
Calib. or Dil.Ratio 3	1/2	2
Calib. or Dil.Ratio 4	1/4	2
Calib. or Dil.Ratio 5	1/8	2
Calib. or Dil.Ratio 6	0/1	2

## Number of Replicates

Special Menu – Settings – Analysis Settings

- Set Replication	Replicates	1
-------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

## ■ Chromogenic Assays





# Application Sheet

## Antithrombin / INNOVANCE® Antithrombin

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

Version	08
Release Date	2024-04
Software Version	≥ 00-17 <sup>a</sup>
USA only	

<sup>a</sup> CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
INNOVANCE® Antithrombin	<b>REF</b> OPFH07	<b>REF</b> OPFH09	<b>REF</b> OPFH11		
• INNOVANCE Antithrombin <b>REAGENT</b>	4 x 2.7 mL	6 x 6.5 mL	4 x 2.7 mL		ATReag
• INNOVANCE Antithrombin <b>SUBSTRATE</b>	4 x 2.7 mL	6 x 6.5 mL	4 x 2.7 mL		ATSub
• INNOVANCE Antithrombin <b>BUFFER</b>	4 x 5 mL	6 x 12 mL	4 x 12 mL		ATBuf
<b>STANDARD PLASMA</b>	<b>REF</b> ORKL19				
	10 x → 1 mL				SHP
<b>CONTROL N</b>	<b>REF</b> ORKE45				
	10 x → 1 mL				n/a
<b>CONTROL P</b>	<b>REF</b> OUPZ19				
	10 x → 1 mL				n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	<b>REF</b> B4265-37				
	8 x 250 mL				OVB
<b>OV</b> <b>BUFFER</b>	<b>REF</b> B4234-25				
	10 x 15 mL				OVB
CA CLEAN I	<b>REF</b> 964-0631-3				
	1 x 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03				
	10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
INNOVANCE Antithrombin <b>REAGENT</b>	4 <sup>b</sup>	–	8
INNOVANCE Antithrombin <b>SUBSTRATE</b>	6 <sup>c</sup>	–	8
INNOVANCE Antithrombin <b>BUFFER</b>	10	–	8
<b>STANDARD PLASMA</b>	#1	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
<b>CONTROL P</b>	Any position on sample rack	–	n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	Buffer position 12	–	n/a
<b>OV</b> <b>BUFFER</b>	Buffer position 12	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position can be used.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	681
Hemoglobin	1 000
Bilirubin	60

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
ATIII / Berichrom® Antithrombin III (A) on CA-500 series	$y = 1.00 \times -0.03 \% \text{ of Norm}$	0.972

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Within-Device CV) on the same lot of control plasma should be as follows:

< 10 %

	Mean (% of Norm)	Repeatability CV (%)	Within- Device/Lab CV (%)
<b>CONTROL N</b>	89.5	2.5	4.3
<b>CONTROL P</b>	29.1	3.2	6.9
Normal plasma pool	97.4	1.3	3.5
Pathological plasma pool	56.6	1.5	4.5

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (% of Norm)	Median (% of Norm)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (% of Norm)
–	150	96.2	96.1	83 – 111

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

<b>Test Protocol Name</b>	AT	<b>STD-Link</b>	No
<b>Manage. ID<sup>e</sup></b>	6000		
Detector	for BCAT3		
Start Point		6 sec	
End Point		21 sec	
Sensitivity	Low Gain		
Wavelength	405 nm	Inc	
Sample Vol		10 µL	
Dil.Vol	ATBuf	110 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		40 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	ATReag	80 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		210 sec	
Reag. Vol	ATSub	80 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>e</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

- Mark Limits	Select Param.	AT %
---------------	---------------	------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

AT%

(%)	(dOD)
135.0	0.299
90.0	0.524
45.0	0.889
22.5	1.137
11.3	1.295
5.6	1.377

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	AT %
Units	%
Number Format	XXX.X
Curve Fit	Log Curve

Standard Curve – Standard Analysis

Select Dilution Set	10
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	3/2	2
Calib. or Dil.Ratio 2	1/1	2
Calib. or Dil.Ratio 3	1/2	2
Calib. or Dil.Ratio 4	1/4	2
Calib. or Dil.Ratio 5	1/8	2
Calib. or Dil.Ratio 6	1/16	2

## Number of Replicates

Special Menu – Settings – Analysis Settings

- Set Replication	Replicates	1
-------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

# Application Sheet

## Antithrombin III / Berichrom® Antithrombin III (A)

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	14
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-660

### Materials Required

Product	Order No.	Order No.	Order No.	Order No.	Name in Test Protocol
• Component(s)	Package Size 1	Package Size 2	Package Size 3	Package Size 4	
Berichrom <b>AT III</b>	<b>REF</b> OWWR17	<b>REF</b> OWWR15			
• Berichrom <b>AT III</b> <b>REAGENT THR</b>	6 × → 5 mL	6 × → 15 mL			AT3Thro
• Berichrom <b>AT III</b> <b>SUBSTRATE</b>	3 × → 3 mL	6 × → 3 mL			AT3Subs
• Berichrom <b>AT III</b> <b>REAGENT THR DILUENT</b>	1 × 30 mL	1 × 100 mL			n/a
<b>STANDARD PLASMA</b>	<b>REF</b> ORKL19				
	10 × → 1 mL				SHP
<b>CONTROL N</b>	<b>REF</b> ORKE45				
	10 × → 1 mL				n/a
<b>CONTROL P</b>	<b>REF</b> OUPZ19				
	10 × → 1 mL				n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	<b>REF</b> B4265-37				
	8 × 250 mL				OVB
<b>OV</b> <b>BUFFER</b>	<b>REF</b> B4234-25				
	10 × 15 mL				OVB
CA CLEAN I	<b>REF</b> 964-0631-3				
	1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03				
	10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
Berichrom <b>AT III</b> <b>REAGENT THR</b>	4 <sup>b</sup>	–	8
Berichrom <b>AT III</b> <b>SUBSTRATE</b>	6 <sup>c</sup>	–	8
Berichrom <b>AT III</b> <b>REAGENT THR DILUENT</b>	n/a	–	n/a
<b>STANDARD PLASMA</b>	#1	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
<b>CONTROL P</b>	Any position on sample rack	–	n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	Buffer position 12	GW 5; SLD Vial <sup>d</sup>	8
<b>OV</b> <b>BUFFER</b>	Buffer position 12	GW 5; SLD Vial	8
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>c</sup> Alternatively, any other non-cooled reagent position can be used.

<sup>d</sup> For positioning on the analyzer, the buffer has to be transferred into an appropriate vial.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	1 200
Hemoglobin	1 000
Bilirubin	60

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>e</sup>
ATIII / Berichrom® Antithrombin III (A) on CA-6000	$y = 0.95 \times + 4.50 \%$ of Norm	0.972

<sup>e</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 10 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
CONTROL N	2.3	4.5	5.0
CONTROL P	2.9	9.5	9.9

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean (% of Norm)	Median (% of Norm)	2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile (% of Norm)
–	285	96.1	96.5	79.1 – 114.1

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

<b>Test Protocol Name</b>	AT3	<b>STD-Link</b>	No
<b>Manage. ID<sup>f</sup></b>	6010		
Detector	for BCAT3		
Start Point		11 sec	
End Point		40 sec	
Sensitivity	Low Gain		
Wavelength	405 nm	Inc	
Sample Vol		10 µL	
Dil.Vol	OVB	83 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		20 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	AT3Thro	125 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		90 sec	
Reag. Vol	AT3Subs	33 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>f</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

<b>– Mark Limits</b>	Select Param.	AT3 %
----------------------	---------------	-------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

AT3 %

(%)	(dOD)
145.5	0.180
97.0	0.507
48.5	0.832
24.3	0.992
12.1	1.065
0.0	1.097

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	AT3 %
Units	%
Number Format	XXX.X
Curve Fit	Lin-Lin

Standard Curve – Standard Analysis

Select Dilution Set	8
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	3/2	2
Calib. or Dil.Ratio 2	1/1	2
Calib. or Dil.Ratio 3	1/2	2
Calib. or Dil.Ratio 4	1/4	2
Calib. or Dil.Ratio 5	1/8	2
Calib. or Dil.Ratio 6	0/1	2

## Number of Replicates

Special Menu – Settings – Analysis Settings

<b>– Set Replication</b>	Replicates	1
--------------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**



# Application Sheet

## Heparin / INNOVANCE® Heparin

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	05
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-27 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-660

### Materials Required

Product • Component(s)	Order No. Package Size 1	Order No. Package Size 2	Order No. Package Size 3	Order No. Package Size 4	Name in Test Protocol
INNOVANCE <b>HEPARIN</b>	<b>REF</b> OPOA05				
• INNOVANCE <b>HEPARIN</b> <b>REAGENT</b>	5 × 3.2 mL				IHepRea
• INNOVANCE <b>HEPARIN</b> <b>SUBSTRATE</b>	5 × 4.0 mL				IHepSub
INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b>	<b>REF</b> OPOB05				
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 1	1 × → 1.0 mL				IHepCal1
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 2	1 × → 1.0 mL				IHepCal2
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 3	1 × → 1.0 mL				IHepCal3
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 4	1 × → 1.0 mL				IHepCal4
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 5	1 × → 1.0 mL				IHepCal5
INNOVANCE <b>HEPARIN</b> <b>LMW CONTROL</b> 1	<b>REF</b> OPOE05				
	5 × → 1 mL				IHepLMW1
INNOVANCE <b>HEPARIN</b> <b>LMW CONTROL</b> 2	<b>REF</b> OPOF05				
	5 × → 1 mL				IHepLMW2
INNOVANCE <b>HEPARIN</b> <b>UF CONTROL</b> 1	<b>REF</b> OPOC05				
	5 × → 1 mL				IHepUF1
INNOVANCE <b>HEPARIN</b> <b>UF CONTROL</b> 2	<b>REF</b> OPOD05				
	5 × → 1 mL				IHepUF2
<b>STANDARD PLASMA</b> <sup>b</sup>	<b>REF</b> ORKL19				
	10 × → 1 mL				SHP
<b>CA SYSTEM</b> <b>BUFFER</b>	<b>REF</b> B4265-37				
	8 × 250 mL				OVB
<b>OV</b> <b>BUFFER</b>	<b>REF</b> B4234-25				
	10 × 15 mL				OVB
CA CLEAN I	<b>REF</b> 964-0631-3				
	1 × 50 mL				Clean I
Sample Cup Conical 4 mL	<b>REF</b> 424-1160-8				
	100 pcs.				n/a
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03				
	10 pcs.				n/a

<sup>b</sup> Only required when extending the measuring range by sample dilution (please also refer to chapter "Measuring Range").

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

## On-board Stability

Component	Position	Condition	Time (h)
INNOVANCE [HEPARIN] [REAGENT]	1 <sup>c</sup>	–	16
INNOVANCE [HEPARIN] [SUBSTRATE]	2 <sup>c</sup>	–	16
INNOVANCE [HEPARIN] [CALIBRATOR 1]	#1–#5	–	4
INNOVANCE [HEPARIN] [CALIBRATOR 2]	#1–#5	–	4
INNOVANCE [HEPARIN] [CALIBRATOR 3]	#1–#5	–	4
INNOVANCE [HEPARIN] [CALIBRATOR 4]	#1–#5	–	4
INNOVANCE [HEPARIN] [CALIBRATOR 5]	#1–#5	–	4
INNOVANCE [HEPARIN] [LMW CONTROL 1]	Any position on sample rack	–	8
INNOVANCE [HEPARIN] [LMW CONTROL 2]	Any position on sample rack	–	8
INNOVANCE [HEPARIN] [UF CONTROL 1]	Any position on sample rack	–	8
INNOVANCE [HEPARIN] [UF CONTROL 2]	Any position on sample rack	–	8
[STANDARD PLASMA]	n/a	–	n/a
[CA SYSTEM] [BUFFER]	Buffer position 12	PV-10 <sup>d</sup>	16
[OV] [BUFFER]	Buffer position 12	PV-10	16
CA CLEAN I	Rinse position 11	PV-10	24

<sup>c</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

<sup>d</sup> For positioning on the analyzer, the buffer has to be transferred into an appropriate vial.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Hemoglobin	134
Bilirubin (unconjugated)	20
Bilirubin (conjugated)	28
Triglycerides	267

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

The performance of this device has not been established in neonate and pediatric patient populations.

Test results obtained from pediatric patient populations may be age dependent. Therefore, each laboratory must follow their regulatory agency guidelines to qualify additional age groups.

## Method Comparison

A study was performed with frozen samples to compare the INNOVANCE® Heparin assay on the CA-660 System to the INNOVANCE® Heparin assay on the BCS® XP System for the measurement of heparin. The results from the Passing-Bablok regression analysis are summarized in the following table:

Predicate Device	Regression Equation	r <sup>e</sup>
Heparin / INNOVANCE® Heparin on BCS® XP (UFH (n=148) and LMWH (n=132) containing samples)	$y = 0.97x - 0.04 \text{ IU/mL}$	0.99

<sup>e</sup> r = Correlation Coefficient

## Precision

The standard deviation (SD) of the analytical system should be as follows:

Samples with heparin activities of  
 $\leq 0.50 \text{ IU/mL [SD]}$   $\leq 0.03 \text{ IU/mL}$

Samples with heparin activities of  
 $> 0.50 \text{ IU/mL [CV]}$   $\leq 7.5 \%$

Precision studies were conducted on the CA-660 according to CLSI guideline EP05-A2, using

INNOVANCE [HEPARIN] [UF CONTROL 1], INNOVANCE [HEPARIN] [UF CONTROL 2], INNOVANCE [HEPARIN] [LMW CONTROL 1], INNOVANCE [HEPARIN] [LMW CONTROL 2] and 6 plasma pools covering the measuring range

The results from the precision studies are summarized in the following table (Calculation of CV (%):  $CV (\%) = SD (IU/mL) \times 100 / Mean (IU/mL)$ ):

	Mean (IU/mL)	Repeatability SD (IU/mL)	Within- Device/Lab SD (IU/mL)
INNOVANCE HEPARIN LMW CONTROL 1	0.40	0.013	0.018
INNOVANCE HEPARIN LMW CONTROL 2	1.00	0.030	0.037
INNOVANCE HEPARIN UF CONTROL 1	0.28	0.015	0.019
INNOVANCE HEPARIN UF CONTROL 2	0.60	0.018	0.022
Plasma pool 1 containing LMWH	0.10	0.016	0.016
Plasma pool 1 containing UFH	0.13	0.013	0.018
Plasma pool 2 containing LMWH	0.65	0.014	0.019
Plasma pool 2 containing UFH	0.98	0.027	0.038
Plasma pool 3 containing LMWH	1.32	0.024	0.024
Plasma pool 3 containing UFH	1.39	0.027	0.028

## Measuring Range

Comments	(IU/mL)
-	0.10 – 1.50

Samples with low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) concentrations above 1.50 IU/mL can be manually diluted by mixing two parts of sample with one part of **STANDARD PLASMA** and subsequent measurement of the diluted sample.

Prior to reporting the result of the manually diluted sample must be multiplied by the dilution factor of 1.5. This procedure results in an extended measuring range of 0.10 to 2.25 IU/mL.

When applying the above described procedure to dilute samples, the antithrombin activity in samples with pathological low antithrombin activities will be compensated. This may lead to an overestimation of the effect of anticoagulation in these patients.

## Expected Values

n/a

## Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	IHep	STD-Link	No
Manage. ID	6130		
Detector	for Chrom 1		
Start Time		20 sec	
End Time		60 sec	
Sensitivity	Low Gain		
Wavelength	405 nm	Inc	
Sample Vol		10 µL	
Dil.Vol	OVB	11 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	IHepSub	100 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		90 sec	
Reag. Vol	IHepRea	75 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

## Data Check

Special Menu – Settings – Data Check

– Mark Limits	Select Param.	IHep
– Replic. Limits	Difference (%)	10
– Report Limits	lower (<)	0.10 IU/mL
	upper (>)	1.50 IU/mL

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	IHep
Units	IU/mL
Number Format	XX.XX
Curve Fit	Lin Pt-Pt

Standard Curve – Standard Analysis

Select Dilution Set	M
Calibrator	INNOVANCE Heparin Calibrator

Refer to the Table of Analytical Values for the lot specific calibrator value.

	Repl.
Calib. or Dil.Ratio 1	Calibrator 1 2
Calib. or Dil.Ratio 2	Calibrator 2 2
Calib. or Dil.Ratio 3	Calibrator 3 2
Calib. or Dil.Ratio 4	Calibrator 4 2
Calib. or Dil.Ratio 5	Calibrator 5 2

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---

### Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

IHep

(IU/mL)	(dOD)
1.55	0.376
1.19	0.444
0.79	0.570
0.42	0.724
0.00	0.929

### Remarks

–





# Application Sheet

## Protein C / Berichrom® Protein C

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

<b>Version</b>	15
<b>Release Date</b>	2024-04
<b>Software Version</b>	≥ 00-17 <sup>a</sup>
<b>USA only</b>	

<sup>a</sup> CA-660

### Materials Required

Product	Order No.	Order No.	Order No.	Order No.	Name in Test Protocol
• Component(s)	Package Size 1	Package Size 2	Package Size 3	Package Size 4	
Berichrom <b>PROTEIN C</b>	<b>REF</b> OUVV15	<b>REF</b> OUVV17			
• Berichrom <b>PROTEIN C</b> <b>ACTIVATOR</b>	3 × → 10 mL	4 × → 5 mL			BCPCAAct
• Berichrom <b>PROTEIN C</b> <b>SUBSTRATE</b>	3 × → 3 mL	2 × → 3 mL			BCPCSub
• Berichrom <b>PROTEIN C</b> <b>ACTIVATOR DILUENT</b>	1 × 30 mL	1 × 30 mL			n/a
<b>STANDARD PLASMA</b>	<b>REF</b> ORKL19				
	10 × → 1 mL				SHP
<b>CONTROL N</b>	<b>REF</b> ORKE45				
	10 × → 1 mL				n/a
<b>CONTROL P</b>	<b>REF</b> OUPZ19				
	10 × → 1 mL				n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	<b>REF</b> B4265-37				
	8 × 250 mL				OVB
<b>OV</b> <b>BUFFER</b>	<b>REF</b> B4234-25				
	10 × 15 mL				OVB
CA CLEAN I	<b>REF</b> 964-0631-3				
	1 × 50 mL				Clean I
BC Vial Kit (empty vials for 5 mL)	<b>REF</b> OVKE03				
	10 pcs.				n/a

### Additional Notes

If reagents, rinse solutions or buffers are not supplied in exactly fitting vials it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into appropriate sample cups.

### On-board Stability

Component	Position	Condition	Time (h)
Berichrom <b>PROTEIN C</b> <b>ACTIVATOR</b>	1 <sup>b</sup>	–	48
Berichrom <b>PROTEIN C</b> <b>SUBSTRATE</b>	2 <sup>b</sup>	–	48
Berichrom <b>PROTEIN C</b> <b>ACTIVATOR DILUENT</b>	n/a	–	n/a
<b>STANDARD PLASMA</b>	#1	–	n/a
<b>CONTROL N</b>	Any position on sample rack	–	n/a
<b>CONTROL P</b>	Any position on sample rack	–	n/a
<b>CA SYSTEM</b> <b>BUFFER</b>	Buffer position 12	–	n/a
<b>OV</b> <b>BUFFER</b>	Buffer position 12	–	n/a
CA CLEAN I	Rinse position 11	PV-10; SLD Vial	24

<sup>b</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	284
Hemoglobin	400
Bilirubin	36

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>c</sup>
Protein C / Berichrom® Protein C on BCT	$y = 1.05x - 1.02\% \text{ of Norm}$	0.963

<sup>c</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Total CV) on the same lot of control plasma should be as follows:  
< 10 %

	Within Run CV (%)	Run to Run CV (%)	Total CV (%)
CONTROL N	1.6	1.0	1.8
CONTROL P	3.6	1.4	3.6

### Measuring Range

The measuring range is defined by the concentration of the calibrators used.

### Expected Values

Refer to the Instructions for Use of the reagent.

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

### Bibliography

Refer to the Instructions for Use of the reagent.



## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

<b>Test Protocol Name</b>	BCPC	<b>STD-Link</b>	No
<b>Manage. ID<sup>d</sup></b>	6200		
Detector	for BCPC		
Start Point		11 sec	
End Point		100 sec	
Sensitivity	Low Gain		
Wavelength	405 nm	Inc	
Sample Vol		20 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		60 sec	
Reag. Vol	BCPCAct	125 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 2		540 sec	
Reag. Vol	BCPCSub	30 µL	
Pre. Rinse	*****		x 0
Post. Rinse	Clean I		x 1
Reagent 3		0 sec	
Reag. Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0

<sup>d</sup> The Management ID only applies to the CA-600 series.

## Data Check

Special Menu – Settings – Data Check

<b>– Mark Limits</b>	Select Param.	BCPC %
----------------------	---------------	--------

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

BCPC%

(%)	(dOD)
97.0	0.148
48.5	0.080
24.3	0.039
12.1	0.019
6.1	0.009
3.0	0.004

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	BCPC%
Units	%
Number Format	XXX.X
Curve Fit	Lin-Lin

Standard Curve – Standard Analysis

Select Dilution Set	1
Calibrator	SHP

Refer to the Table of Analytical Values for the lot specific calibrator value.

		Repl.
Calib. or Dil.Ratio 1	1/1	2
Calib. or Dil.Ratio 2	1/2	2
Calib. or Dil.Ratio 3	1/4	2
Calib. or Dil.Ratio 4	1/8	2
Calib. or Dil.Ratio 5	1/16	2
Calib. or Dil.Ratio 6	1/32	2

## Number of Replicates

Special Menu – Settings – Analysis Settings

<b>– Set Replication</b>	Replicates	1
--------------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

## Immunoassays



# Application Sheet

## D-dimer /

### INNOVANCE® D-Dimer

For additional information, limitations and interferences please refer to the Instructions for Use of the analyzer and check current Instructions for Use for reagents, controls and calibrators and tables of assigned/analytical values.

The parameters defined in this application sheet have been developed by Siemens Healthineers to provide optimal product performance with the assay and instrument combination. Any modification to these parameters may affect performance of this and other assays in use on your system and the resulting assay values. It is the responsibility of the user to validate any modifications and their impact on all assay results. Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

The application sheet lists all combinations of controls and calibrators for use with the reagent and instrument system; other combinations are not validated or supported by Siemens Healthineers.

Version	11
Release Date	2024-04
Software Version	≥ 00-17 <sup>a</sup>
USA only	

<sup>a</sup> CA-660

## Materials Required

Product	Order No.	Order No.	Order No.	Order No.	Name in Test Protocol
• Component(s)	Package Size 1	Package Size 2	Package Size 3	Package Size 4	
INNOVANCE® D-Dimer	[REF] OPBP09	[REF] OPBP11			
• INNOVANCE D-Dimer [REAGENT]	3 x → 4 mL	6 x → 4 mL			DDi.REA
• INNOVANCE D-Dimer [BUFFER]	3 x 5 mL	6 x 5 mL			DDi.BUF
• INNOVANCE D-Dimer [SUPPLEMENT]	3 x 2.6 mL	6 x 2.6 mL			DDi.SUP
• INNOVANCE D-Dimer [DILUENT]	3 x 5 mL	6 x 5 mL			DDi.DIL
• INNOVANCE D-Dimer [CALIBRATOR]	2 x → 1 mL	2 x → 1 mL			n/a
• [EMPTY VIAL]	1 x 12 pcs.				n/a
INNOVANCE® D-Dimer Controls	[REF] OPDY09				
• INNOVANCE D-Dimer [CONTROL 1]	5 x → 1 mL				n/a
• INNOVANCE D-Dimer [CONTROL 2]	5 x → 1 mL				n/a
INNOVANCE D-Dimer [DILUENT]	[REF] OPBR03				
	10 x 5 mL				DDi.DIL
[CA SYSTEM] [BUFFER]	[REF] B4265-37				
	8 x 250 mL				OVB
[OV] [BUFFER]	[REF] B4234-25				
	10 x 15 mL				OVB

## Additional Notes

If reagents, rinse solutions or buffers are not supplied in vials, which fit on the instrument exactly it is necessary to transfer them into appropriate vials.

The required controls and calibrators have to be transferred into Sample Cup Conical 4 mL, [REF] 424-1160-8.

Push vials (Push Vial PV-10, [REF] 541-1352-1) and 5 mL vials from the BC Vial Kit (empty vials for 5 mL), [REF] OVKE03 can be used as appropriate vials for reagents, rinse solutions or buffers that are not supplied in vials that fit exactly on the instrument.

## On-board Stability

Component	Position	Condition	Time (h)
INNOVANCE D-Dimer [REAGENT]	6 <sup>b</sup>	–	16
	6 <sup>b</sup>	Sample Cup Conical 4 mL	4
INNOVANCE D-Dimer [BUFFER]	4 <sup>c</sup>	–	16
	4 <sup>c</sup>	Sample Cup Conical 4 mL	4
INNOVANCE D-Dimer [SUPPLEMENT]	8 <sup>b</sup>	–	16
	8 <sup>b</sup>	Sample Cup Conical 4 mL	4
INNOVANCE D-Dimer [DILUENT]	10	–	16
	10	Sample Cup Conical 4 mL	4
INNOVANCE D-Dimer [CALIBRATOR]	#1	–	n/a
INNOVANCE D-Dimer [CONTROL 1]	Any position on sample rack	–	n/a
INNOVANCE D-Dimer [CONTROL 2]	Any position on sample rack	–	n/a

Component	Position	Condition	Time (h)
CA SYSTEM   BUFFER	Buffer position 12	GW 5; SLD Vial	48
OV   BUFFER	Buffer position 12	GW 5; SLD Vial	48

<sup>b</sup> Alternatively, any other non-cooled reagent position can be used.

<sup>c</sup> Alternatively, any other cooled reagent position can be used.

Please note: If reagents recommended for cooling are stored on a non-cooled position, a reduced on-board stability has to be anticipated.

In original vials, the reagents may be left on board the instrument continuously for 16 hours or stored on and off the instrument for intervals of 7 × 1 hour over a maximum period of 14 days.

Storage and stability are described in the Instructions for Use. INNOVANCE® D-Dimer controls need to validate each new test run.

The stability data presented here were established under controlled laboratory conditions. Due to differences in laboratory environmental conditions and reagent vial filling volumes, the on-board stability may deviate from the above-mentioned values.

## Interference Studies

No interferences up to ...	(mg/dL)
Triglycerides	400
Hemoglobin	200
Bilirubin	12

### Limitations

Higher levels of lipids or turbid samples can lead to falsely elevated or decreased values. It is therefore recommended to perform an additional centrifugation step of the plasma (10 minutes at approx. 15 000 x g) before analyzing lipemic patient specimens.

## Performance Characteristics

The following studies were conducted using specimens collected in 3.2 % sodium citrate solution.

### Method Comparison

Predicate Device	Regression Equation	r <sup>d</sup>
D-dimer / INNOVANCE® D-Dimer on BCS®	$y = 1.09x - 0.03$ mg/L FEU	0.994

<sup>d</sup> r = Correlation Coefficient

### Precision

The coefficient of variation of the analytical system (Within-Device CV) on the same lot of control plasma should be as follows:

< 15 %

	Mean (mg/L FEU)	Repeatability CV (%)	Within- Device/Lab CV (%)
INNOVANCE D-Dimer CONTROL 1	0.30	5.3	6.7
INNOVANCE D-Dimer CONTROL 2	2.69	3.9	5.2

### Measuring Range

The INNOVANCE® D-Dimer measuring range is defined by the concentration of the calibrator used and is approximately 0.19 to 4.40 mg/L FEU. The measuring range can be extended to approximately 35.20 mg/L FEU by a manually requested redilution of samples above the measuring range with the +DDi setting.

## Clinical Performance

### Exclusion of DVT

The INNOVANCE® D-Dimer assay was evaluated on the CA-560 Coagulation Analyzer in a multi-center study to validate the exclusion of DVT using fresh specimens collected from 455 consecutive patients presenting to the emergency department with suspected DVT. Of these 455 patients, 31 were excluded for a total of 424 patients available for final analysis.

All patients were evaluated using the Wells' rules to estimate a likely or unlikely pre-test probability (PTP) of DVT. Patient specimens were tested with the INNOVANCE® D-Dimer assay and results were compared to a cutoff value of

0.50 mg/L FEU. A D-dimer result < 0.50 mg/L FEU was considered negative and a D-dimer result ≥ 0.50 mg/L FEU was considered positive.

Patients with a positive D-dimer result were evaluated by imaging methods, e.g. compression ultrasound and/or venography. Patients with a negative D-dimer, as well as those with negative imaging results, were followed for three months to evaluate potential development of DVT. All patients were subject to imaging at the physician's discretion. The overall prevalence of DVT in those patients available for final analysis was 22.2 % (94/424). The following instrument-specific sensitivity, specificity and negative predictive value (NPV) with upper and lower 95 % confidence limits (CL) were obtained with the INNOVANCE® D-Dimer clinical cutoff of 0.50 mg/L FEU.

	DVT Patients n	Cutoff [mg/L FEU]	Sensitivity (CL) %	Specificity (CL) %	NPV (CL) %
All patients	424	0.50	98.9 (94.2 - 100.0)	37.3 (32.0 - 42.7)	99.2 (95.6 - 100.0)
Patients with unlikely pre-test probability	267	0.50	100.0 (83.9 - 100.0)	39.8 (33.7 - 46.3)	100.0 (96.3 - 100.0)

#### Exclusion of PE

The INNOVANCE® D-Dimer was evaluated on the CA-500/CA-600 series in a multi-center study to validate the exclusion of PE using fresh specimens collected from 701 consecutive patients presenting to the emergency department with suspected PE. Of these 701 patients, 60 were excluded for a total of 641 patients available for final analysis.

All patients were evaluated using the Wells' rules to estimate a high, moderate or low pre-test probability (PTP) of PE. Patient specimens were tested with the INNOVANCE® D-Dimer assay and results were compared to a cutoff value of 0.50 mg/L FEU. A D-dimer result < 0.50 mg/L FEU was considered negative and a D-dimer result ≥ 0.50 mg/L FEU was considered positive.

Patients with a positive D-dimer result and/or a high PTP were evaluated by imaging methods, e.g. spiral CT and/or VQ scan. Patients with a negative D-dimer result and a low or moderate PTP (these patients underwent imaging at the physician's discretion), and patients with negative imaging results, were followed for three months to evaluate potential development of PE.

The overall prevalence of PE in those patients available for final analysis was 13.7 % (88/641). The following instrument-specific sensitivity, specificity and negative predictive value (NPV) with upper and lower 95 % confidence limits (CL) were obtained with the INNOVANCE® D-Dimer clinical cutoff of 0.50 mg/L FEU.

	PE Patients n	Cutoff [mg/L FEU]	Sensitivity (CL) %	Specificity (CL) %	NPV (CL) %
All patients	641	0.50	96.6 (90.4 - 99.3)	39.4 (35.3 - 43.6)	98.6 (96.1 - 99.7)
Patients with low and moderate pre-test probability	610	0.50	95.8 (88.1 - 99.1)	40.3 (36.1 - 44.5)	98.6 (96.1 - 99.7)

#### Expected Values

In a study with ostensibly healthy subjects the following data were obtained:

Comments	n	Mean	Median (mg/L FEU)	90 <sup>th</sup> percentile (mg/L FEU)
–	150	–	0.25	0.59

Reference intervals vary from laboratory to laboratory depending on the population, the technique and reagent lot. Therefore, each laboratory must establish its own reference intervals or verify them whenever one or more of the aforementioned variables are changed.

For more information on establishing reference intervals see CLSI document EP28-A3c, "Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory"; Approved Guideline.

#### Bibliography

Refer to the Instructions for Use of the reagent.

## Test Protocol

Special Menu – Settings – Analysis Settings – Test Protocol

Test Protocol Name	DDi	STD-Link	Master
Manage. ID <sup>e</sup>	6500		
Detector	for IMMUNO2 <sup>f</sup>		
Sensitivity	Low Gain		
Wavelength	575 nm	Inc	
Sample Vol		8 µL	
Dil.Vol	DDi.DIL	12 µL	
Pre. Rinse	OVB		x 1
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		0 µL	
Dil.Vol	*****	0 µL	
Pre. Rinse	*****		x 0
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	DDi.SUP	16 µL	
Pre. Rinse	*****		x 0
Post. Rinse	OVB		x 1
Reagent 2		60 sec	
Reag. Vol	DDi.BUF	80 µL	
Pre. Rinse	*****		x 0
Post. Rinse	OVB		x 1
Reagent 3		180 sec	
Reag. Vol	DDi.REA	44 µL	
Pre. Rinse	OVB		x 1
Post. Rinse	OVB		x 1

<sup>e</sup> The Management ID only applies to the CA-600 series.

<sup>f</sup> For the CA-600 series, it is also possible to select the detector "for DD INN".

## Data Check

Special Menu – Settings – Data Check

– Replic. Limits	Difference (%)	20
– Report Limits	lower (<)	0.19 mg/L
	upper (>)	4.40 mg/L

## Standard Curve (example only)

A new standard curve must be established when changing a reagent lot, after major maintenance or service, if indicated by quality control results and when required by laboratory control procedures and/or government regulations.

DDi

(mg/L)	(dOD)
5.30	0.1896
2.65	0.1401
1.33	0.0768
0.66	0.0345
0.33	0.0143
0.17	0.0074

## Standard Curve Calibration

### Calibration Parameter 1

Standard Curve – Select Param.

Param.	DDi
Units	mg/L
Number Format	XX.XX
Curve Fit	Log Curve

Standard Curve – Standard Analysis

Select Dilution Set	1
Calibrator	DDi.CAL

Refer to the Table of Analytical Values for the lot specific D-Dimer concentration of INNOVANCE D-Dimer **CALIBRATOR**.

	Repl.
Calib. or Dil.Ratio 1	1/1 2
Calib. or Dil.Ratio 2	1/2 2
Calib. or Dil.Ratio 3	1/4 2
Calib. or Dil.Ratio 4	1/8 2
Calib. or Dil.Ratio 5	1/16 2
Calib. or Dil.Ratio 6	1/32 2

## Number of Replicates

Special Menu – Settings – Analysis Settings

– Set Replication	Replicates	1
-------------------	------------	---



## Test Protocol

Special Menu – Settings – Analysis Settings – **Test Protocol**

Test Protocol Name	+DDi	STD-Link	DDi
Manage. ID <sup>g</sup>	6510		
Detector	for IMMUNO2 <sup>h</sup>		
Sensitivity	Low Gain		
Wavelength	575 nm	Inc	
Sample Vol		10 µL	
Dil.Vol	DDi.DIL	70 µL	
Pre. Rinse	OVB		x 1
Post. Rinse	*****		x 0
2nd Dil			
D.Samp Vol		8 µL	
Dil.Vol	DDi.DIL	12 µL	
Pre. Rinse	OVB		x 1
Post. Rinse	*****		x 0
Reagent 1		30 sec	
Reag. Vol	DDi.SUP	16 µL	
Pre. Rinse	*****		x 0
Post. Rinse	OVB		x 1
Reagent 2		60 sec	
Reag. Vol	DDi.BUF	80 µL	
Pre. Rinse	*****		x 0
Post. Rinse	OVB		x 1
Reagent 3		180 sec	
Reag. Vol	DDi.REA	44 µL	
Pre. Rinse	OVB		x 1
Post. Rinse	OVB		x 1

<sup>g</sup> The Management ID only applies to the CA-600 series.

<sup>h</sup> For the CA-600 series, it is also possible to select the detector "for DD INN".

## Data Check

Special Menu – Settings – **Data Check**

- Replic. Limits	Difference (%)	20
- Report Limits	lower (<)	3.65 mg/L
	upper (>)	35.20 mg/L

## Remarks

The units of measure for INNOVANCE® D-Dimer assay are mg/L FEU. The software of the instrument reports only mg/L. Both, DDi and +DDi should be set in the test group setting to enable manual sample redilution if the standard curve range is exceeded.

All samples above the upper report limit should be repeated using the appropriate +DDi setting again. The redilution has to be requested manually.

### Important!

The parameters given in the Application Sheet have to be entered into the software carefully. Additionally, there are parameters which have to be entered by a Siemens Healthineers service representative only. Please contact your local service.

## Standard Curve Calibration

Not applicable - Standard curve for "DDi" will be used automatically. Ensure that the STD-Link in the test protocol is set to "DDi". For more information refer to Operator`s Manual.

## Number of Replicates

Special Menu – Settings – **Analysis Settings**

- Set Replication	Replicates	1
-------------------	------------	---

---

**Siemens Healthineers Headquarters**  
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen/Germany  
Phone: +49 9131 84-0  
siemens-healthineers.com



**Siemens Healthcare Diagnostics Products GmbH**  
Emil-von-Behring-Str. 76  
35041 Marburg/Germany

**RxOnly**

## Addendum I General Information to the Applications

### On-board Stability

The on-board stability of CA CLEAN I for all applications is 24 hours (in PV-10 or SLD Vial).

### Reportable Ranges

The validation of the reportable ranges on the CA-600 series analyzers includes data generated during the clinical evaluations and software defined limits.

Parameter Reagent/Assay	Unit	Reportable Range
<b>Prothrombin Time</b> <i>Dade® Innovin® Reagent</i> <i>Thromborel® S Reagent</i>	seconds	8.9–93.6
<b>Prothrombin Time (Maximum Time extended to 300 seconds)</b> <i>Dade® Innovin® Reagent</i>	seconds	8.9–170.9
<b>Activated Partial Thromboplastin Time</b> <i>Dade® Actin® Activated Cephaloplastin Reagent</i> <i>Dade® Actin® FS Activated PTT Reagent</i> <i>Dade® Actin® FSL Activated PTT Reagent</i> <i>Pathromtin® SL Reagent</i>	seconds	17.8–176.1
<b>Activated Partial Thromboplastin Time (Maximum Time extended to 600 seconds)</b> <i>Dade® Actin® FSL Activated PTT Reagent</i>	seconds	17.8–192.4
<b>Fibrinogen (Clauss)</b> <i>Dade® Thrombin Reagent</i>	g/L	0.5–8.4 or limits of calibrator
<b>Fibrinogen (Clauss)</b> <i>Multifibren® U Reagent</i>	g/L	0.7–8.0 or limits of calibrator
<b>Thrombin Time</b> <i>Test Thrombin Reagent</i>	seconds	13.5–70.2
<b>Batroxobin Time</b> <i>Batroxobin Reagent</i>	seconds	15.4–84.2
<b>Extrinsic Factors <sup>a</sup></b> Coagulation Factor VII with <i>Dade® Innovin® Reagent</i>	% of norm	10–147 or limits of calibrator
<b>Intrinsic Factors <sup>a</sup></b> Coagulation Factor VIII with <i>Dade® Actin® FSL Activated PTT Reagent</i>	% of norm	7–141 or limits of calibrator
<b>Protein C, coagulometric</b> <i>Protein C Reagent</i>	% of norm	10–150 or limits of calibrator
<b>Antithrombin</b> INNOVANCE® <i>Antithrombin Assay</i>	% of norm	3.1–124.2 or limits of calibrator
<b>Antithrombin III</b> <i>Berichrom® Antithrombin III (A) Assay</i>	% of norm	2–142 or limits of calibrator
<b>Heparin</b> <i>Berichrom® Heparin Assay</i>	IU/mL	0.035–0.641 or limits of calibrator
<b>Protein C</b> <i>Berichrom® Protein C Assay</i>	% of norm	10–180 or limits of calibrator
<b>D-Dimer</b> INNOVANCE® <i>D-Dimer Assay</i>	mg/L (FEU)	0.19–4.40 up to 35.20 or limits of calibrator

<sup>a</sup> Data evaluated for FVII and FVIII only.

## Addendum II Symbol Names of Required Materials, REF and SMN for all products

Symbol names are depicted onto the reagent labels and are not translatable. In the following table symbol names and corresponding product names in the language of this Reference Guide are listed.

Symbol Name	Product Name	REF	SMN
<b>ACTIN FS</b>	Dade® Actin® FS Activated PTT Reagent	B4218-20 B4218-100	10445712 10445710
<b>ACTIN FSL</b>	Dade® Actin® FSL Activated PTT Reagent	B4219-1 B4219-2	10445713 10445714
<b>ACTIN</b>	Dade® Actin® Activated Cephaloplastin Reagent	B4218-1 B4218-2	10445709 10445711
Batroxobin <b>REAGENT</b>	Batroxobin Reagent	OUOV21	10446463
Berichrom <b>AT III</b>	Berichrom® Antithrombin III (A)	OWWR17 OWWR15	10446673 10446672
• Berichrom <b>AT III REAGENT THR</b>	• Thrombin Reagent		
• Berichrom <b>AT III SUBSTRATE</b>	• Substrate Reagent		
• Berichrom <b>AT III REAGENT THR DILUENT</b>	• Buffer Solution		
Berichrom <b>PROTEIN C</b>	Berichrom® Protein C	OUVV15 OUVV17	10446499 10446500
• Berichrom <b>PROTEIN C ACTIVATOR</b>	• Protein C Activator		
• Berichrom <b>PROTEIN C SUBSTRATE</b>	• Substrate Reagent		
• Berichrom <b>PROTEIN C ACTIVATOR DILUENT</b>	• Hepes Buffer Solution		
CA CLEAN I	CA CLEAN I	964-0631-3	11694304
<b>CA SYSTEM BUFFER</b>	Dade® CA System Buffer	B4265-37	10873440
<b>CONTROL N</b>	Control Plasma N	ORKE45	10446235
<b>CONTROL P</b>	Control Plasma P	OUPZ19	10446472
CaCl <sub>2</sub> <b>SOLUTION</b>	Calcium Chloride Solution	ORHO37	10446232
Ci-Trol <b>CONTROL 1</b>	Dade® Ci-Trol® Coagulation Control Level 1	B4244-10	10445731
Ci-Trol <b>CONTROL 2</b>	Dade® Ci-Trol® Coagulation Control Level 2	B4244-20	10445732
Ci-Trol <b>CONTROL 3</b>	Dade® Ci-Trol® Coagulation Control Level 3	B4244-30	10445733
Dade® Innovin®	Dade® Innovin®	B4212-41 B4212-51 B4212-101	10873566 10873567 10873568
Data-Fi <b>FIBRINOGEN CONTROL</b>	Dade® Data-Fi® Abnormal Fibrinogen Control Plasma	B4233-22	10445719
<b>FACTOR VII DEFICIENT</b>	Coagulation Factor VII Deficient Plasma	OTXV13	10446407
<b>FACTOR VIII DEFICIENT</b>	Coagulation Factor VIII Deficient Plasma	OTXW17	10446411
<b>FIBRINOGEN CALIBRATOR</b>	Fibrinogen Calibrator Kit	OQVK11	10446148
• <b>CALIBRATOR 1</b>	• Fibrinogen Calibrator, level 1		
• <b>CALIBRATOR 2</b>	• Fibrinogen Calibrator, level 2		
• <b>CALIBRATOR 3</b>	• Fibrinogen Calibrator, level 3		
• <b>CALIBRATOR 4</b>	• Fibrinogen Calibrator, level 4		
• <b>CALIBRATOR 5</b>	• Fibrinogen Calibrator, level 5		
• <b>CALIBRATOR 6</b>	• Fibrinogen Calibrator, level 6		
<b>FIBRINOGEN DETERMINATION</b>	Dade® Fibrinogen Determination Reagents	B4233-17SY	10873571
• <b>THROMBIN REAGENT</b>	• Dade® Thrombin Reagent		
• <b>FIBRINOGEN STANDARD</b>	• Dade® Fibrinogen Standard		
• <b>OV BUFFER</b>	• Dade® Owren's Veronal Buffer		
INNOVANCE D-Dimer <b>DILUENT</b>	INNOVANCE® D-Dimer Sample Diluent	OPBR03	10487039

Symbol Name	Product Name	REF	SMN
INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b>	INNOVANCE® Heparin Calibrator	OPOB05	10873530
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 1	• INNOVANCE® Heparin Calibrator 1		
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 2	• INNOVANCE® Heparin Calibrator 2		
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 3	• INNOVANCE® Heparin Calibrator 3		
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 4	• INNOVANCE® Heparin Calibrator 4		
• INNOVANCE <b>HEPARIN</b> <b>CALIBRATOR</b> 5	• INNOVANCE® Heparin Calibrator 5		
INNOVANCE <b>HEPARIN</b> <b>LMW CONTROL</b> 1	INNOVANCE® Heparin LMW Control 1	OPOE05	10873534
INNOVANCE <b>HEPARIN</b> <b>LMW CONTROL</b> 2	INNOVANCE® Heparin LMW Control 2	OPOF05	10873533
INNOVANCE <b>HEPARIN</b> <b>UF CONTROL</b> 1	INNOVANCE® Heparin UF Control 1	OPOC05	10873531
INNOVANCE <b>HEPARIN</b> <b>UF CONTROL</b> 2	INNOVANCE® Heparin UF Control 2	OPOD05	10873532
INNOVANCE <b>HEPARIN</b>	INNOVANCE® Heparin	OPOA05	10873535
• INNOVANCE <b>HEPARIN</b> <b>REAGENT</b>	• INNOVANCE® Heparin Reagent		
• INNOVANCE <b>HEPARIN</b> <b>SUBSTRATE</b>	• INNOVANCE® Heparin Substrate		
INNOVANCE® Antithrombin	INNOVANCE® Antithrombin	OPFH07	10487304
		OPFH09	10487303
		OPFH11	10709521
• INNOVANCE Antithrombin <b>REAGENT</b>	• INNOVANCE® Antithrombin reagent		
• INNOVANCE Antithrombin <b>SUBSTRATE</b>	• INNOVANCE® Antithrombin substrate		
• INNOVANCE Antithrombin <b>BUFFER</b>	• INNOVANCE® Antithrombin buffer		
INNOVANCE® D-Dimer Controls	INNOVANCE® D-Dimer Controls	OPDY09	10446006
• INNOVANCE D-Dimer <b>CONTROL</b> 1	• INNOVANCE® D-Dimer Control 1		
• INNOVANCE D-Dimer <b>CONTROL</b> 2	• INNOVANCE® D-Dimer Control 2		
INNOVANCE® D-Dimer	INNOVANCE® D-Dimer	OPBP09	10445981
		OPBP11	10445982
• INNOVANCE D-Dimer <b>REAGENT</b>	• INNOVANCE® D-Dimer reagent		
• INNOVANCE D-Dimer <b>BUFFER</b>	• INNOVANCE® D-Dimer buffer		
• INNOVANCE D-Dimer <b>SUPPLEMENT</b>	• INNOVANCE® D-Dimer supplementary reagent		
• INNOVANCE D-Dimer <b>DILUENT</b>	• INNOVANCE® D-Dimer Sample Diluent		
• INNOVANCE D-Dimer <b>CALIBRATOR</b>	• INNOVANCE® D-Dimer Calibrator		
Multifibren® U	Multifibren® U	OWZG19	10446689
		OWZG23	10446691
<b>OV</b> <b>BUFFER</b>	Dade® Owren's Veronal Buffer	B4234-25	10445724
<b>PROTEIN C</b> <b>COAG</b>	Protein C Reagent	OQYG11	10446185
• <b>PROTEIN C</b> <b>COAG</b> <b>ACTIVATOR</b>	• Protein C Activator		
• <b>PROTEIN C</b> <b>COAG</b> <b>REAGENT</b> <b>APTT</b>	• APTT Reagent for Protein C		
• <b>PROTEIN C</b> <b>COAG</b> <b>DEFICIENT</b>	• Protein C Deficient Plasma		
Pathromtin® SL	Pathromtin® SL	OQGS29	10446066
		OQGS35	10446067
<b>STANDARD PLASMA</b>	Standard Human Plasma	ORKL19	10487098
<b>TEST THROMBIN</b>	Test Thrombin Reagent	OWHM13	10446598
• <b>TEST THROMBIN</b> <b>REAGENT</b>	• Test Thrombin Reagent		
• <b>TEST THROMBIN</b> <b>REAGENT DILUENT</b>	• Buffer Solution		
<b>THROMBIN</b> <b>REAGENT</b>	Dade® Thrombin Reagent	B4233-25	10445720
		B4233-27	10445721
Thromborel® S	Thromborel® S	OUIP53	10873565